These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29161692)

  • 1. Association between Extreme Values of Markers of Chronic Kidney Disease: Mineral and Bone Disorder and 5-Year Mortality among Prevalent Hemodialysis Patients.
    Zhu JG; Chen JB; Cheng BC; Lee CH; Long G; Chien YS
    Blood Purif; 2018; 45(1-3):1-7. PubMed ID: 29161692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.
    Soohoo M; Feng M; Obi Y; Streja E; Rhee CM; Lau WL; Wang J; Ravel VA; Brunelli S; Kovesdy CP; Kalantar-Zadeh K
    Am J Nephrol; 2016; 43(2):85-96. PubMed ID: 26950688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.
    Block GA; Kilpatrick RD; Lowe KA; Wang W; Danese MD
    Clin J Am Soc Nephrol; 2013 Dec; 8(12):2132-40. PubMed ID: 24052218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.
    Lee SA; Lee MJ; Ryu GW; Jhee JH; Kim HW; Park S; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Yoo TH
    Osteoporos Int; 2016 Sep; 27(9):2717-2726. PubMed ID: 27216997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.
    Ogata H; Kumasawa J; Fukuma S; Mizobuchi M; Kinugasa E; Fukagawa M; Fukuhara S; Akizawa T
    Clin Exp Nephrol; 2017 Oct; 21(5):797-806. PubMed ID: 28508128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines.
    Liu Y; Lee WC; Cheng BC; Li LC; Lee CH; Chang WX; Chen JB
    Biomed Res Int; 2016; 2016():1523124. PubMed ID: 28003998
    [No Abstract]   [Full Text] [Related]  

  • 7. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CKD-MBD Markers with All-Cause Mortality in Prevalent Hemodialysis Patients: A Cohort Study in Beijing.
    Li D; Zhang L; Zuo L; Jin CG; Li WG; Chen JB
    PLoS One; 2017; 12(1):e0168537. PubMed ID: 28045985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan.
    Maruyama Y; Taniguchi M; Kazama JJ; Yokoyama K; Hosoya T; Yokoo T; Shigematsu T; Iseki K; Tsubakihara Y
    Nephrol Dial Transplant; 2014 Aug; 29(8):1532-8. PubMed ID: 24642419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient.
    Heaf JG
    Perit Dial Int; 2015 Nov; 35(6):640-4. PubMed ID: 26702005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Transplant Outcomes in Peritoneal and Hemodialysis Patients: A Meta-Analysis.
    Tang M; Li T; Liu H
    Blood Purif; 2016; 42(2):170-6. PubMed ID: 27296631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in kano, northwest nigeria.
    Abdu A; Abdu A; Arogundade FA
    Ann Afr Med; 2019; 18(4):191-195. PubMed ID: 31823953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
    Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
    Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease.
    Lukowsky LR; Molnar MZ; Zaritsky JJ; Sim JJ; Mucsi I; Kovesdy CP; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2012 Jul; 27(7):2899-907. PubMed ID: 22207323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.